Luca Gerosa

Senior Scientist

Genentech Inc
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Supplementary Figure S4: (A) NCI-H358-RIT1M90I cells are resistant to divarasib single agent treatment and can be re-sensitized with divarasib and migoprotafib combination both in vitro and in vivo.

Year:

2025

Supplementary Table S1: Assessment of immunohistochemistry staining intensity on lungs from RIT1 mice. Pathological findings are summarized for all tumors within each animal. Localization of CD3-positive T cells is described. IHC staining intensity is qualitatively scored as +++; strongly positive, +/-; mixed and description is included, -; negative.

Year:

2025

RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered “oncogene-negative” and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated a murine model of RIT1 M90I -mutant lung cancer. RIT1 M90I expression induced tumorigenesis in the lungs, and the tumors displayed histopathologic features similar to lung adenocarcinoma in humans. An unbiased chemical compound screen leveraging this model revealed a sensitivity to inhibitors of the MAPK, PI3K, and cholesterol biosynthesis pathways in RIT1-mutant cell lines. The SHP2 inhibitor, migoprotafib, in combination with other MAPK pathway–targeted therapies, effectively suppressed the growth of RIT1-mutant cells ex vivo and in vivo . Finally, RIT1 M90I drove resistance to the KRAS G12C inhibitor, divarasib, and the combination with migoprotafib reverted this phenotype. Together, these data show that RIT1 M90I is a bona fide oncogenic driver of lung cancer and a mediator of targeted therapy resistance as a co-occurring mutation and suggest that patients with RIT1-altered cancer may benefit from combination treatments with an SHP2 inhibitor. Significance: Development of a mouse model of RIT1 M90I -altered non-small cell lung cancer reveals that RIT1 M90I is a driver of lung tumorigenesis and that RIT1-mutated tumors are sensitive to MAPK pathway inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by Mozzarelli et al., p. 3196

Year:

2025

Recent advances in single-cell studies have unveiled the extensive transcriptomic heterogeneity of cancer-associated fibroblasts (CAFs), with each subset potentially playing unique roles in the tumor microenvironment. Despite these insights, it remains unclear how to culture different subsets of CAFs in vitro while preserving their in vivo phenotype. The inherent plasticity of CAFs, characterized by their ability to dynamically alter their phenotype in response to various environmental stimuli, presents significant challenges in inducing and maintaining specific CAF states in vitro. In this study, we investigated the effects of cell shape and confinement on two-dimensional culture substrates on the transcriptomic profile and phenotype of cultured CAFs. By inducing cytoskeletal rearrangement and activating mechanotransductory pathways through micropatterning of polyacrylamide hydrogels, we observed significant shape- and confinement-dependent changes in cell morphology. Our results showed that micropatterned CAFs exhibited phenotypic shifts towards more myofibroblastic, desmoplastic and inflammatory subsets. Additionally, micropatterning allowed for control over a range of CAF-specific markers and pathways, significantly altering their transcriptome landscape and behavior. Lastly, we demonstrated that micropatterned and non-micropatterned CAFs responded differently to anti-cancer drugs, underscoring the importance of phenotype-oriented therapy that accounts for CAF plasticity and regulatory networks. Control over CAF morphology through micropatterning presents a unique opportunity to establish highly robust CAF phenotypes in vitro, thereby facilitating a deeper understanding of CAF plasticity and heterogeneity. This approach also holds promise for the development of novel therapeutic targets, as it allows for the precise manipulation of CAF states to better model and study their interactions within the tumor microenvironment. Citation Format: Aleksandr Mitriashkin, Josephine Yu Yan Yap , N. Gopalakrishna Iyer , Gianluca Grenci, Eliza Li Shan Fong. Cell confinement by micropatterning induces phenotypic changes in cancer-associated fibroblasts [abstract]. In: Proceedings of Frontiers in Cancer Science 2024; 2024 Nov 13-15; Singapore. Philadelphia (PA): AACR; Cancer Res 2025;85(15_Suppl):Abstract nr LT03.

Year:

2025

RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered “oncogene-negative” and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated a murine model of RIT1M90I-mutant lung cancer. RIT1M90I expression induced tumorigenesis in the lungs, and the tumors displayed histopathologic features similar to lung adenocarcinoma in humans. An unbiased chemical compound screen leveraging this model revealed a sensitivity to inhibitors of the MAPK, PI3K, and cholesterol biosynthesis pathways in RIT1-mutant cell lines. The SHP2 inhibitor, migoprotafib, in combination with other MAPK pathway–targeted therapies, effectively suppressed the growth of RIT1-mutant cells ex vivo and in vivo. Finally, RIT1M90I drove resistance to the KRASG12C inhibitor, divarasib, and the combination with migoprotafib reverted this phenotype. Together, these data show that RIT1M90I is a bona fide oncogenic driver of lung cancer and a mediator of targeted therapy resistance as a co-occurring mutation and suggest that patients with RIT1-altered cancer may benefit from combination treatments with an SHP2 inhibitor. Significance: Development of a mouse model of RIT1M90I-altered non-small cell lung cancer reveals that RIT1M90I is a driver of lung tumorigenesis and that RIT1-mutated tumors are sensitive to MAPK pathway inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by Mozzarelli et al., p. 3196

Year:

2025

Purpose: This study explores the potential of preclinical in vitro cell line response data and computational modeling in identifying optimal dosage requirements of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma treatment. Our research is motivated by the critical role of drug combinations in enhancing anti-cancer responses and the need to close the knowledge gap around selecting effective dosing strategies to maximize their potential. Results: In a drug combination screen of 43 melanoma cell lines, we identified unique dosage landscapes of panRAF and MEK inhibitors for NRAS vs BRAF mutant melanomas. Both experienced benefits, but with a notably more synergistic and narrow dosage range for NRAS mutant melanoma. Computational modeling and molecular experiments attributed the difference to a mechanism of adaptive resistance by negative feedback. We validated in vivo translatability of in vitro dose-response maps by accurately predicting tumor growth in xenografts. Then, we analyzed pharmacokinetic and tumor growth data from Phase 1 clinical trials of Belvarafenib with Cobimetinib to show that the synergy requirement imposes stricter precision dose constraints in NRAS mutant melanoma patients. Conclusion: Leveraging pre-clinical data and computational modeling, our approach proposes dosage strategies that can optimize synergy in drug combinations, while also bringing forth the real-world challenges of staying within a precise dose range. Simple Summary Combining drugs is crucial for enhancing anti-cancer responses. However, the potential of pre-clinical data in identifying suitable combinations and dosage is often underutilized. In this study, we leverage preclinical in vitro cell line drug response data and computational modeling of signal transduction and of pharmacokinetics to elucidate distinct dose requirements for the combination of pan-RAF and MEK inhibitors in melanoma. Our findings reveal a more synergistic, but narrower dosing landscape in NRAS vs BRAF mutant melanoma, which we linked to a mechanism of adaptive resistance through negative feedback. Further, our analysis suggests the importance of drug dosing strategies to optimize synergy based on mutational context, yet highlights the real-world challenges of maintaining a narrow dose range. This approach establishes a framework for translational investigation of drug responses in the refinement of combination therapy, balancing the potential for synergy and practical feasibility in cancer treatment planning.

Year:

2024

Collaborators (1)

Danilo Maddalo

Group Leader

Genentech Inc

UNITED STATES
View details